Courses

During this introduction to the science behind a wide variety of systemic treatments given to people with prostate, bladder, or kidney cancer, Dr Elaine Vickers will discuss current hormone therapies, immunotherapy and targeted treatments.

The 4Ps Programme has been developed by research active healthcare professionals in Newcastle and is designed to support colleagues' needs no matter where they are on the “research interested” to “Aspiring Clinical Academic” continuum

A focus on modern systemic treatments for non-small cell lung cancer (NSCLC) as well as the gene faults that drive many NSCLCs; the targeted treatments that exploit these faults, such as inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, MET, and RET; the immune system and checkpoint inhibitor group of immunotherapies, including PD-1, PD-L1 and CTLA-4 targeted antibody therapies